País: Irlanda
Língua: inglês
Origem: HPRA (Health Products Regulatory Authority)
PAROXETINE MESYLATE
Genthon BV
PAROXETINE MESYLATE
20 Milligram
Film Coated Tablet
Product subject to prescription which may not be renewed (A)
Authorised
0000-00-00
Common Technical Document Paroxetine (as mesilate) 20 mg film-coated tablets Synthon Hispania Module 1 - Section 3.5 Core SPC, Labelling and Package Leaflet page 1/15 issue date:06-06-2011 version:M1.3.1_03.POT.tab20.005.18.IE.239.02. approved: TV BA 1.3.1 Core Package Leaflet PACKAGE LEAFLET: INFORMATION FOR THE USER MELOXAT 20 MG, FILM-COATED TABLETS Active substance: paroxetine (as mesilate) READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU . Keep this leaflet. You may need to read it again. If you have any further questions, ask your doctor or pharmacist. This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. WHAT IS IN THIS LEAFLET: 1. What Meloxat is and what it is used for 2. Waht you need to know before you take Meloxat 3. How to take Meloxat 4. Possible side effects 5. How to store Meloxat 6. Contents of the pack and other information 1. WHAT MELOXAT IS AND WHAT IT IS USED FOR Paroxetine belongs to the group of medicines known as selective serotonin re- uptake inhibitors (SSRIs), which are antidepressants. Meloxat is used for the treatment of: Depressive illness (major depressive episode) Obsessive compulsive disorder (obsessive compulsive thoughts or actions) Panic disorder with or without agoraphobia (e.g. strong fear of leaving the house, entering shops, or fear of public Leia o documento completo
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Meloxat 20 mg film-coated tablets. 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each film-coated tablet contains paroxetine mesilate equivalent to 20 mg paroxetine base. Excipients with known effect: Each tablet contains 3.81 mg lactose monohydrate. For the full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Film-coated tablet. Round yellow film-coated tablets that are embossed with "POT 20" on one side and scored on both sides. The tablet can be divided into equal doses. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Treatment of - Major Depressive Episode - Obsessive Compulsive Disorder - Panic Disorder with and without agoraphobia - Social Anxiety Disorders/Social phobia - Generalised Anxiety Disorder - Post-traumatic Stress Disorder 4.2 POSOLOGY AND METHOD OF ADMINISTRATION It is recommended that paroxetine is administered once daily in the morning with food. The tablet should be swallowed rather than chewed. MAJOR DEPRESSIVE EPISODE The recommended dose is 20 mg daily. In general, improvement in patients starts after one week but may only become evident from the second week of therapy. As with all antidepressant medicinal products, dosage should be reviewed and adjusted if necessary within 3 to 4 weeks of initiation of therapy and thereafter as judged clinically appropriate. In some patients, with insufficient response to 20 mg, the dose may be increased gradually up to a maximum of 50 mg a day in 10 mg steps according to the patient's response. Patients with depression should be treated for a sufficient period of at least 6 months to ensure that they are free from symptoms. OBSESSIVE COMPULSIVE DISORDER The recommended dose is 40 mg daily. Patients should start on 20 mg/day and the dose m Leia o documento completo